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Abstracts / Osteoarthritis and Cartilage 23 (2015) A26eA81A72OA hip patients and 19 were neck of femur (NOF) fracture patients free of
OA. Genome-wide DNA methylation proﬁling was carried out on the
bisulphite converted DNA of these 110 patients using the Inﬁnium
HumanMethylation450 BeadChip (Illumina). For each CpG, the data was
represented as a b value ranging from 0 (no methylation) to 1 (100%
methylation). A replication cohort of 47 elderly individuals (29 OA knee,
13OAhip and 5NOF samples)was taken forward formethylation analysis
by pyrosequencing. Genotyping was performed on the cartilage DNA
using the HumanOmniExpress Bead Chip (Illumina) for the 110 patients
and RFLP assays for the 47 patients. Gene expression comparisons were
performed using previously published data and directly by real-time
quantitative PCR on cartilage cDNA. Sixteen OA risk loci were studied,
including well-deﬁned candidates such as GDF5 and DIO2, and signals
fromgenome-wide association scans such as those from the arcOGENand
Rotterdam studies. Genotype at the SNP that had originally identiﬁed the
association signal was correlated with CpG methylation levels by logistic
regression. For each locus we covered the whole association interval (as
deﬁnedby linkagedisequilibrium) and studied all of the CpGs fromwithin
that region that are part of the HumanMethylation450 BeadChip array.
The number of CpGs therefore ranged from 57 (the chromosome 9q
arcOGEN locus) to 655 (the MCF2L locus). P-values were corrected for
multiple testing using the Benjamini-Hochberg method and were
adjusted for the number of CpGs studied. For the discovery phase we
studied the methylation data for all 110 individuals and following strat-
iﬁcation to OA-only (91 individuals). If relevant, we also investigated the
particular strata of OA that had originally been used to detect the asso-
ciation signal. For example, the arcOGEN RUNX2/SUPT3H locus (dis-
covered using SNP rs10948172) is only relevant to disease occurrence in
males and we therefore studied males-only as part of our analysis of this
locus. The same stratiﬁed approach was applied to the replication cohort.
Results: In the discovery analysis of the 110 patients ﬁve of the 16 risk
loci harbored CpGs whose methylation correlated with genotype at the
association SNP. These were the GNL3/GLT8D1, RUNX2/SUPT3H, MCF2L,
ALDH1A2 and GDF5 loci. Themost signiﬁcant p-valuewas 9.42x10-9 for
CpG probe cg18099408 within the GNL3/GLT8D1 locus. All 5 signals
replicated and in the same direction as in the discovery analysis
(p<0.05), with the p-value for cg18099408 in the replication cohort
being 0.009. The RUNX2/SUPT3H locus demonstrated a correlation
between genotype and methylation status only in the male strata,
perfectly matching the genetic result for this locus. For this locus,
methylation of four CpGs that cluster together correlated with genotype
at rs10948172, with the most signiﬁcant p-value being 4.4x10-7 for CpG
probe cg18551225. All four CpGs replicated in males (p<0.05). Gene
expression correlated with methylation at 3 of the 5 replicating signals
but not with MCF2L or RUNX2/SUPT3H, implying that the functional
effects at these two loci may have been active during earlier stages of
cartilage development.
Conclusions: Our study reveals that a high proportion of OA suscepti-
bility loci correlate with and therefore potentially regulate the level of
DNA methylation in cis, so called methylation quantitative trait loci or
meQTLs. It therefore provides us with a mechanistic explanation as to
how these loci impact upon OA susceptibility, with DNA methylation
acting as an intermediary of OA genetic risk.
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THE CARBOHYDRATE SULFOTRANSFERASE GENE CHST11 IS
REGULATED BY DNA METHYLATION WHICH IMPACTS ON THE
FUNCTIONAL EFFECT OF THE OA GENETIC SUSCEPTIBILITY
RESIDING AT THIS LOCUS
L.N. Reynard, J. Loughlin. Newcastle Univ., Newcastle upon Tyne, United
Kingdom
Purpose: The carbohydrate sulfotransferase gene CHST11 encodes an
enzyme that plays an important role in chondrogenesis by regulating the
sulphation of glycosaminoglycans in the cartilage extracellular matrix.
SNP rs835487, located within the gene, is associated with hip OA at the
genome-wide signiﬁcance level in European populations (p¼1.64x10-8).
Several CpG sites within CHST11 are aberrantly methylated in human OA
cartilage and this gene is up-regulated in both OA hip and OA knee car-
tilage. We have previously reported allelic differences in enhancer
activity of rs835487 and of rs835488, which is in perfect linkage dis-
equilibriumwith rs835487, forming a single haplotype. This allelic effect
is mediated by differences in binding of the transcription regulator
proteins SP1, SP3, YY1 and SUB1 to the two alleles of the haplotype.
rs835487 and rs835488 reside within intron 2 of CHST11 in an enhancerregion that we hypothesis acts as a regulator of CHST11 expression. There
are several CpG sites within this enhancer region, including one created
by the C allele of rs835488, suggesting DNA methylation could modulate
the OA genetic effect on CHST11 enhancer activity. The aims of this study
were to: A) determine if DNA methylation regulates CHST11 expression;
B) examine if there is altered methylation of the rs835487-rs835488
enhancer region in OA cartilage, and if so; C) understand what affect this
has on protein binding to and regulatory activity of the enhancer.
Methods: Isolated human primary chondrocytes (HACs) and trans-
formed human cell lines were cultured with the demethylating agent 5-
aza-2ʹdeoxycytidine (AZA) for 3 population doublings and CHST11
expression measured by qRT-PCR. Methylation of 3 CpG sites within the
enhancer was assayed by pyrosequencing after bisulphite conversion of
genomic DNA that was extracted frommacroscopically normal cartilage
obtained fromOA hip, OA knee or neck-of-femur (NOF) fracture patients
after joint replacement surgery. The CpG sites were located 10bp
downstream of rs835487, rs835488 itself and 34bp downstream of
rs835488. The affect of DNA methylation on protein binding to and
enhancer activity of the rs835487 and rs835488 SNPs was investigated
using electrophoretic mobility shift assays (EMSAs) and in-vitro
methylation luciferase assays respectively.
Results: CHST11 was upregulated in HACs (2-fold, p¼0.008) and human
cell lines after AZA treatment. All 3 enhancer CpG sites assayed were
signiﬁcantly hypermethylated inOAhip andOAknee cartilage relative to
the NOF control cartilage (p<0.0001). Methylation level of the rs835488
CpG site was affected by rs835488 genotype in OA cartilage (OA hip
CT¼17.3%, CC¼33.2%; OA knee CT¼16.4%, CC¼29.6%), but, surprisingly,
not in NOF cartilage, where individuals homozygous and heterozygous
for the CpG site had similar levels of methylation (CT¼10%, n¼14;
CC¼12.1%, n¼15). Methylation of the 3 enhancer CpG sites also corre-
lated with additional CHST11 CpG sites outside of this region (up to
100kb away), including the cg00608861 and cg11117177 CpG sites pre-
viously identiﬁed as differentially methylated in OA cartilage. Again,
these correlations were speciﬁc to OA cartilage, with the strongest cor-
relations observed in OA hip cartilage. In EMSAs, methylation of the
rs835487 þ10CpG site increased binding of an unknown protein spe-
ciﬁcally to theAallele of rs835487but hadnoaffect on thebindingof SP1,
SP3 or SUB1 to either allele. SP1, SP3, YY1 and SUB1 boundmore avidly to
the methylated C allele than unmethylated C allele of rs835488, with an
unidentiﬁed protein-complex binding only to the methylated allele.
Methylation therefore represses enhancer activity of the rs835487-
rs835488 region in a haplotype-dependent manner.
Conclusions: Our results demonstrate that methylation of the
rs835487-rs835488 enhancer region has a signiﬁcant effect on tran-
scription factor binding to these OA susceptibility SNPs, with methyl-
ation altering the regulatory activity of this region. There is therefore a
clear functional link between genetic risk and methylation status at the
CHST11 OA susceptibility locus. Since DNA methylation is inﬂuenced by
lifestyle, age and disease status our data implies that the functional
effect of the rs835487 and rs835488 risk haplotype may change under
different environmental situations, affecting its penetrance on OA risk.
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DIFFERENTIAL DNA METHYLATION AND REDUCED EXPRESSION OF
CRITICAL TRANSCRIPTION FACTORS IN HUMAN OA CARTILAGE
O. Alvarez-Garcia, K.M. Fisch, R. Akagi, A.I. Su, M.K. Lotz. The Scripps Res.
Inst., La Jolla, CA
Purpose: DNA methylation is the most characterized epigenetic
mechanism and has been recently linked to knee osteoarthritis (OA)
pathogenesis. While genome wide methylation studies have shown
substantial differences between normal and OA articular cartilage,
those studies have important limitations: a) most studies compared OA
articular cartilage from different joints without including a proper
control group, b) the functional consequences of differentially methy-
lated genomes were normally assessed by transcriptional analysis of a
small group of genes of interest, and c) the resulting link between DNA
methylation and transcription was not further validated in an exper-
imental setting. All these limitations prompted us to design a study
aimed to comprehensively integrate the methylome and transcriptome
of normal and OA knee articular cartilage using the Illumina Inﬁnium
HumanMethylation450 beadchip array and next generation RNA
sequencing, respectively. Furthermore, we used different in vitro
approaches to experimentally validate the link between DNA methyl-
ation and gene expression in human chondrocytes.
Abstracts / Osteoarthritis and Cartilage 23 (2015) A26eA81 A73Methods: Genomic DNA was isolated from human macroscopically pre-
served (N¼11) and OA (N¼12) knee articular cartilage. After bisulphite
treatment, DNA was proﬁled using the Illumina Inﬁnium Human-
Methylation450 beadchip. For transcriptomic analysis, RNA isolated from
normal (N¼8) and OA (N¼10) knee articular cartilage was sequenced
using the Illumina HiSeq 2000 platform. In both cases, normalized data
was analyzed using a custom-made R bioconductor package. For in vitro
experiments, primary chondrocytes isolated from donors with normal
(N¼5) cartilage, and TC28 immortalized chondrocytes were used. Cells
were cultured inmonolayer until conﬂuence, treatedwith different doses
of the DNA methylation inhibitor 5-Aza-2-deoxycytidine (5’Aza) or
vehicle, and gene expression was assessed by qPCR.
Results: DNA methylation proﬁling revealed 3259 differentially methy-
lated sites (DMS) between normal and OA cartilage (p<0.05, FDR0.15)
that comprised a total of 1269 genes. Compared with all the CpG sites
included in the array, DMSwere signiﬁcantly enriched in gene bodies and
enhancer regions of the genome, and depleted in CpG islands and pro-
moter regions. Integrative analysis with RNAseq data showed that only
127 out of 1269 genes were also differentially transcribed in OA cartilage.
To assess the functional consequences of the different methylation
landscapes, we identiﬁed 73 genes that showed an inverse correlation
between methylation and gene expression. Interestingly, this group of
genes included a subset of 10 transcription factors that were signiﬁcantly
hypermethylated and downregulated in OA cartilage (ATOH8, FOXO3,
KLF15, MAFF, NCOR2, NFATC1, RARA, TBX4, ZBTB16 and ZHX2). In vitro
experiments in TC28 cells treated with 5’Aza showed a signiﬁcant pos-
itive correlation between 5’Aza concentration and gene expression for
ATOH8, FOXO3, KLF15, MAFF, NCOR2, RARA, TBX4 and ZBTB16. However,
in primary chondrocytes only FOXO3 and TBX4 showed a signiﬁcant
increase in gene expression upon 5’Aza treatment.
Conclusions: The present results reveal a striking correlation between a
relatively large number of transcription factors that were hyper-
methylated and downregulated in OA cartilage. These ﬁndings suggest
that methylation-related changes of several important transcription
factors represent an important mechanism that may explain changes in
chondrocyte transcriptome and function in OA.
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INSIGHTS INTO OSTEOARTHRITIS PROGRESSION REVEALED BY
ANALYSES OF BOTH KNEE TIBIOFEMORAL COMPARTMENTS
C.-H. Chou y, M. Lee z, I.-W. Song x, L.-S. Lu x, J.-Y. Wu x, Y.-T. Chen x,
V.B. Kraus y, C.-C. Wu k. yDuke Univ., Durham, NC, USA; zRIKEN Ctr. for
Genomic Med., Yokohama, Japan; x Inst. of BioMed. Sci., Academia Sinica,
Taipei, Taiwan; k Tri-Service Gen. Hosp., Natl. Defense Med. Ctr., Taipei,
Taiwan
Purpose: Although the progression of osteoarthritis (OA) is generally
currently unpredictable, altered biomechanical and biochemical prop-
erties of the joint organ facilitate progression of disease. It is widely
accepted that the molecular homeostasis of the joint depends on both
the structural integrity of articular cartilage and the appropriate bio-
mechanical stresses. A detailed examination of molecular changes in
cartilage is of pivotal importance for choosing molecules that could
potentially be targeted to achieve a therapeutic beneﬁt. However,
results of molecular analyses of advancedmedial compartment knee OA
tissue may not only represent direct effects of disease, but also site-
related effects driven by altered mechanical loading. To overcome these
obstacles, we have pursued a two-pronged approach. First cartilage
gene expression changes relative to a gradient of histological OA
severity across the tibial plateau in knees with medial compartment
dominant disease (MOA) (Figure panel A) were proﬁled to identify
disease relevant and potential OA progression related genes. Second,
cartilage gene expression changes relative to a gradient of histological
OA severity across the tibial plateau in knees with lateral compartment
dominant disease (LOA) were used to validate this OA progression
model system (Figure panel B). Because load plays less of a role in
development of LOA than MOA, we hypothesized that the identiﬁcation
of the severity associated genes expressed in common between medial
and lateral compartment dominant disease may more readily identify
genes related to biological factors directly associated with OA pro-
gression that are independent of load.
Methods: We evaluated histological and transcriptomic changes of
regions of interest across the tibial plateau encompassing a wide range
of disease severities (Figure A-D). Gene expression of knee cartilage was
comprehensively assessed for three regions of interest across the tibialplateau from human medial dominant OA (n¼10) and non-OA (n¼6)
specimens. Histology and gene expression were compared for the
regions with minimal degeneration, moderate degeneration and sig-
niﬁcant degeneration. Agilent whole-genome microarray was per-
formed and data were analyzed using Agilent GeneSpring GX11.5.
Signiﬁcant differentially regulated genes were further investigated by
Ingenuity Pathway Analysis (IPA) to identify functional categories. To
conﬁrm their associationwith disease severity as opposed to site within
the knee, 30 differentially expressed genes, identiﬁed by microarray,
were analyzed by quantitative reverse-transcription polymerase chain
reaction on additional medial (n¼16) and lateral (n¼10) compartment
dominant knee OA samples.
Results: A total of 767 genes were differentially expressed >two-fold (P
0.05) in lesion compared to relatively intact regions. Analysis of these
data by IPA predicted biological functions related to an imbalance of
anabolism and catabolism of cartilage matrix components. Up-regu-
lated expression of IL11, POSTN, TNFAIP6, and down-regulated expres-
sion of CHRDL2, MATN4, SPOCK3, VIT, PDE3B were signiﬁcantly
associated with OA progression and validated in both medial and lateral
compartment dominant OA samples (Figure E).
Conclusions: A comparison between MOA and LOA gene expression
was applied in our study to characterize differentially expressed genes
that may represent genes directly involved with OA disease progression
as opposed to site-related effects driven by altered mechanical loading.
Our study provides a strategy for identifying targets whose mod-
iﬁcation may have the potential to ameliorate pathological alternations
and progression of disease in cartilage and to serve as biomarkers for
identifying individuals susceptible to progression.
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RISK PREDICTION USING EPIGENETIC PROFILES IN BLOOD OF
OSTEOARTHRITIS PATIENTS
Y.F. Ramos, W. den Hollander, N. Lakenberg, R. van der Breggen,
N. Bomer, H. Kroon, M. Kloppenburg, P. Slagboom, I. Meulenbelt. Leiden
Univ. Med. Ctr., Leiden, Netherlands
Purpose: Previous studies have highlighted the urgent need for bio-
markers to predict OA progression in the clinic, preferably with an AUC
